Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 34 of 45

Comparative Adverse Effects of Combining DMARDs

Combining methotrexate (MTX) or other oral disease-modifying anti-rheumatic drugs (DMARDs) with a biologic DMARD does not alter the adverse event rate found with the biologic DMARD alone. The strength of evidence for this finding is low.

Combining MTX and biologic DMARDs demonstrates a better tolerability profile than MTX alone. The strength of evidence for this finding is low.

Evidence is insufficient to estimate differences in rates of specific adverse events between the biologic and oral DMARDs.